RT Journal Article
SR Electronic
T1 Infliximab induced T lymphocyte apoptosis in Crohn's disease.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 26
OP 30
VO 74
A1 Jan van den Brande
A1 Daan W Hommes
A1 Maikel P Peppelenbosch
YR 2005
UL http://www.jrheum.org/content/74/26.abstract
AB Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract of unknown origin. Therapies include immune modulating agents, biological therapies, and surgery. The activity and efficacy of the anti-tumor necrosis factor (TNF) therapies infliximab and etanercept have proved to be different: infliximab is effective to induce and maintain remission in refractory CD, while etanercept is not. This brief review considers the question of whether this disparity can be explained by the different structure of the proteins, their different binding affinities, or the subsequent effects on T lymphocytes.